Clinical Trials Search
Clinical Trial 20484
Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT04511130
Phase: Phase II
Prinicipal Investigator: Nelli Bejanyan
Study Title
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell Transplantation
Summary
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).
Objective
Primary: Safety Lead-in: To assess safety and tolerability of MT-401 Phase 2: Adjuvant (Group 1): To compare relapse-free survival (RFS) for MT-401 (Arm A) vs standard of care (SOC; Arm B) Active Disease (Group 2): To estimate complete remission (CR) and duration of CR (DOCR) Secondary (Efficacy): Safety Lead in: To assess efficacy of MT-401 Phase 2 (Adjuvant Group 1): >To analyze overall survival (OS) for MT-401 (Arm A) and SOC (Arm B); >To compare graft-versus-host disease RFS (GRFS) for MT-401 (Arm A) vs SOC (Arm B). Phase 1 (Active Disease Group 2): >To evaluate overall response rate (ORR), duration of complete remission (DOR), progression-free survival (PFS) and OS for MT 401 alone; > To evaluate RFS, OS, and GRFS for patients who achieve CR following bridging therapy. Secondary (Safety): Phase 2 (Groups 1 and 2): >To evaluate the safety and tolerability of administering donor-derived MT 401 to patients with AML post-HSCT
Therapies
Medications
MT-401 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.